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Abstract
Multiple myeloma (MM) causes lytic bone lesions due to increased bone resorption and 
concomitant marked suppression of bone formation. Sclerostin (Scl) levels, an osteocyte-derived 
inhibitor of Wnt/β-catenin signaling, are elevated in MM patient sera and are increased in 
osteocytes in MM-bearing mice. We show here that genetic deletion of Sost, the gene encoding 
Scl, prevented MM-induced bone disease in an immune-deficient mouse model of early MM, and 
that administration of anti-Scl antibody (Scl-Ab) increased bone mass and decreases osteolysis in 
immune-competent mice with established MM. Sost/Scl inhibition increased osteoblast numbers, 
stimulated new bone formation and decreased osteoclast number in MM-colonized bone. Further, 
Sost/Scl inhibition did not affect tumor growth in vivo or anti-myeloma drug efficacy in vitro. 
These results identify the osteocyte as a major contributor to the deleterious effects of MM in bone 
and osteocyte-derived Scl as a promising target for the treatment of established MM-induced bone 
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disease. Further, Scl did not interfere with efficacy of chemotherapy for MM suggesting that 
combined treatment with anti-myeloma drugs and Scl-Ab should effectively control MM growth 
and bone disease, providing new avenues to effectively control MM and bone disease in patients 
with active MM.
Introduction
Multiple myeloma (MM) is characterized by the clonal expansion of malignant plasma cells 
within the bone marrow, production of monoclonal immunoglobulin (paraprotein), and end 
organ damage, including lytic lesions in bone, renal dysfunction, hypercalcemia, and anemia 
(1, 2). MM bone disease (MMBD) is characterized by extensive bone resorption and 
protracted suppression of osteoblast function, resulting in bone lesions that are purely lytic 
and rarely heal, even in patients with long-term complete remission (1, 2). Current anti-
myeloma regimens have significantly increased the life expectancy for MM patients, but 
have minor effects on bone repair (3). Therefore, MM patients live longer but continue to 
suffer from the devastating skeletal sequelae. Thus, new therapeutic regimens that 
simultaneously target tumor progression and improve MMBD are greatly needed.
MM cell growth, bone disease, and resistance to therapy are highly dependent on the bone/
bone marrow microenvironment. Thus, targeting the interactions between malignant plasma 
cells and the multiple cell types present in MM microenvironment is required to successfully 
treat MM (2, 4). The contributions of tumor cells, osteoclasts, osteoblasts, stromal cells, and 
immune cells to MMBD are well known (1, 4, 5). However, the role of osteocytes in MM is 
just starting to emerge (6–9). Osteocytes, the most numerous bone cells, are key regulators 
of physiologic bone remodeling and a major source of factors that regulate osteoclast and 
osteoblast activity (10–12). Further, dysregulation of osteocyte function and alteration of 
osteocyte lifespan underlies the pathophysiology of several skeletal disorders (13), and 
pharmacological targeting of osteocyte-derived factors markedly affects bone homeostasis 
(14). Recent studies demonstrate that osteocytes are also important contributors to MMBD 
(6, 9).
Sclerostin (Scl), the product of the Sost gene, is a potent Wnt/β-catenin antagonist 
preferentially expressed by osteocytes in the adult skeleton. Scl achieves its bone effects by 
binding to the lipoprotein receptor-related proteins (LRP) 4/5/6 and blocking Wnt/β-catenin 
signaling to modulate both bone formation and bone resorption (15–17). Neutralizing 
monoclonal antibodies against Scl (Scl-Ab) increase bone mass in both experimental 
animals and humans, by a dual mechanism that includes increased bone formation and 
decreased bone resorption (18, 19). Thus, Scl has quickly become a promising therapeutic 
target for the treatment of skeletal diseases characterized by low bone mass.
Since Sost/Scl expression is increased in osteocytes in a murine model of MM (6), and Scl 
levels are elevated in the sera of MM patients and correlate with reduced osteoblast function 
and poor patient survival (20, 21), we examined the potential of Scl as a therapeutic target 
for MMBD. We report that genetic deletion of Sost prevents MM-induced bone loss in an 
immune-deficient mouse model of early MM, and that treatment with Scl-Ab reduces 
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osteolysis and increases cancellous bone volume in immune-competent mice with 
established MM.
Methods
Antibodies and compounds
Reagents used in this study are described in Supplementary Methods.
Mouse model of human MM
Immune-deficient mice with global deletion of Sost (Sost−/−/Scid) were generated by 
crossing Sost−/− mice (22) with B6.CB17-Prkdcscid/SzJ Scid mice (Jackson laboratories, 
Bar Harbor, Maine, USA). Six-wk-old Sost−/−/Scid and control littermate mice (wt/Scid) 
were injected intratibially with 105 human JJN3 myeloma cells or saline and sacrificed 4wks 
later (6). Six to 10 female and male mice per group were used for these experiments. Six-
wk-old immune-competent C57BLKaLwRij (23, 24) mice were injected intratibially with 
105 murine 5TGM1 myeloma cells or saline. After four weeks, tumor engraftment was 
confirmed, mice were stratified by IgG2b levels, and then control mice and mice bearing 
MM were treated with either Scl-Ab (15mg/kg/wk) or control antibody (IgG) for four 
additional weeks, when the mice were sacrificed. Seven to 10 female and male mice per 
group were used for these experiments. Sample size for these studies was calculated based 
on previous studies (6, 25). Mice were fed with a regular diet (Harlan, Indianapolis, IN), 
received water ad libitum, and were maintained on a 12-hour light/dark cycle. Studies were 
approved by the Institutional Animal Care and Use Committee of the Indiana University 
School of Medicine.
Analysis of the skeletal phenotype
BMD measurements, radiographs, and micro-CT analyses were performed as previously 
described (6, 26). BioQuant software (Nashville, TN) was used to determine osteolytic 
lesion area. Histomorphometric analyses were performed as previously published (26), and 
expressed as recommended (27). All these analyses were performed in a blinded fashion.
Serum biochemistry
Human Kappa Light chain and murine IgG2b circulating levels were determined using 
enzyme-linked immunosorbent assays (ELISA) kits (Bethyl Laboratories, Inc., Montgomery, 
TX). N-terminal propeptide of type I procollagen (P1NP) and C-terminal telopeptides of 
type I collagen (CTX) circulating levels were quantified as previously published (26).
Immunohistochemistry
Scl, TRAPase and von Kosa staining methods are described in Supplementary Methods.
Cells and culture conditions
Myeloma cells were treated for 48 hours with BTZ (3-5-10 nM), DEX (10−6-10−5-10−4 M), 
or GSI-XX (5-10-20 μM) in the presence or absence of Scl-Ab (5 μg/mL). DMSO and IgG 
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(5 μg/mL) were used as controls. Viable cells were enumerated by trypan blue exclusion as 
previously published (6).
Statistics
Statistical methods are described in Supplementary Methods.
Results
Genetic deletion of Sost decreases osteolysis and prevents bone loss induced by MM 
without affecting MM tumor progression
We generated mice with a global deletion of Sost in an immune-deficient Scid background 
(Sost−/−/Scid) (Fig. 1a). At 6-wks of age, Sost−/−/Scid mice displayed the expected high 
bone mass phenotype associated with Sost deficiency (22), with increased bone mineral 
density at all skeletal sites, as well as increased bone volume (BV/TV) and improved bone 
architecture in the cancellous bone of the tibia (Fig. 1b and 1e). Sost−/−/Scid and wt/Scid 
mice injected with human JJN3 myeloma cells had equivalent tumor engraftment (Fig. 1c). 
However, X-ray analyses revealed that the number and area of osteolytic lesions were 
reduced in Sost−/−/Scid mice by 60% and 74%, respectively, compared to wt/Scid mice (Fig. 
1d). JJN3-injected wt/Scid mice had a ~50% decrease in tibia cancellous BV/TV and 
trabecular number (Tb.N), and a non-significant increase in trabecular separation (Tb.Sp) 
(Fig. 1e). In contrast, JJN3-injected Sost−/−/Scid mice displayed no changes in BV/TV or 
bone architecture compared to saline-injected Sost−/−/Scid mice. These results demonstrate 
that Sost deficiency in vivo protects mice from MM-induced bone loss without affecting 
tumor growth.
Sost−/−/Scid mice are protected from the decrease in osteoblast number and function 
induced by MM
To establish the cellular mechanisms underlying the protective effects of Sost deficiency on 
bone mass in mice bearing MM, osteoblasts and osteoclasts numbers, and osteoblast 
function were quantified in the cancellous bone of the proximal tibia (Fig 2a). Sost−/−/Scid 
mice exhibited increased bone formation (BFR/BS) and osteoblasts (Fig. 2a and 2b), but no 
changes in osteoclasts (Fig. 2c), compared to control wt/Scid littermates. JJN3-injected wt/
Scid mice displayed decreased mineral apposition (MAR) and BFR (Fig. 2a), reduced bone 
surface covered by osteoblasts (Ob.S/BS) and lower numbers of osteoblasts (Ob.N/BS) (Fig. 
2b), as well as increased osteoclast surface (Oc.S/BS) and number (Oc.N/BS) (Fig. 2c). 
Strikingly, osteoblast surface/number or osteoblast function remained elevated in JJN3-
injected Sost−/−/Scid mice and indistinguishable from saline-injected Sost−/−/Scid mice (Fig. 
2b). In addition, JJN3-injected Sost−/−/Scid mice had increased osteoclasts compared to 
saline-injected Sost−/−/Scid mice, although the results did not reach statistical significance 
(Fig. 2c). These results demonstrate that Scl contributes to the decrease in osteoblast number 
and function and the increase in osteoclasts induced by myeloma cells.
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Administration of Scl-Ab reduces osteolysis and increases cancellous bone mass in mice 
with established MM, without altering tumor growth
We next examined the effect of pharmacological inhibition of Scl in an immune-competent 
mouse model of established MM (Fig. 3a). C57BL/KaLwRij mice injected with murine 
5TGM1 myeloma cells exhibited ~2-fold increase in the levels of IgG2b 4-wks after 
myeloma cell injection (0.36±0.01 vs. 0.08±0.02, saline- and 5TGM1-injected respectively, 
p ≤ 0.01). After 4-wks of treatment, serum IgG2b levels were similar in 5TGM1-injected 
mice receiving Scl-Ab or IgG (Fig. 3b). No evidence of extramedullary disease was detected 
and the distribution of 5TGM1 myeloma cells in the marrow cavity of mice receiving Scl-Ab 
and IgG was similar (Fig. 3c). 5TGM1-injected mice had increased numbers of Scl-positive 
osteocytes in cortical and cancellous bone (Fig. 3d), that was not altered by Scl-Ab 
administration.
Scl-Ab reduced the number of osteolytic lesions by 46% compared to the IgG-treated mice 
(Fig. 3e). Further, 5TGM1-injected mice and receiving IgG injections had ~35% decreased 
BV/TV and Tb.N, and increased Tb.Sp (Fig. 3f). In contrast, mice receiving Scl-Ab, 
regardless of whether they were injected with 5TGM1 myeloma cells or not, displayed 
increased trabecular BV/TV (52%), Tb.N (22%), Tb.Th (33%) and decreased Tb.Sp (14%) 
compared to saline-injected mice receiving IgG (Fig. 3f). Taken together, these results 
support that Scl contributes to bone loss in mice with established MM, but not to MM 
growth.
Scl-Ab therapy reduces osteolysis and increases cancellous bone mass in mice with 
established MM
We next investigated the cellular basis for the bone gain in mice bearing MM treated with 
Scl-Ab. In saline-injected mice, Scl-Ab increased osteoblast surface and number and the 
serum levels of the bone formation marker P1NP (Fig. 4a and c); and decreased osteoclast 
surface, without significant changes in osteoclast numbers or in the circulating levels of the 
bone resorption marker CTX (Fig. 4b and c). Mice with established MM and receiving IgG 
exhibited decreased osteoblast surface/number and a non-significant decrease in serum 
P1NP (Fig. 4a), and increased osteoclast surface/number but no detectable changes in serum 
CTX (Fig. 4b). Scl-Ab similarly increased osteoblast surface/number and serum P1NP in 
5TGM1-injected mice or saline-injected mice (Fig. 4a). Further, 5TGM1-injected mice 
receiving Scl-Ab still exhibited increased osteoclast surface and osteoclast number, although 
these changes did not reach statistical significance (Fig. 4b). Thus, Scl-Ab treatment 
increases osteoblast number and function and partially decreases osteoclasts in bones 
colonized by myeloma cells.
Scl-Ab does not alter the anti-MM activity of Bortezomib, Dexamethasone, or a Notch 
inhibitor
As expected, BTZ, DEX and GSIXX decreased the number of viable JJN3 and 5TGM1 
myeloma cells in a dose-dependent manner (Fig. 5a). Consistent with the lack of effect of 
the Scl-Ab on MM growth in vivo, Scl-Ab did not affect the viability of JJN3 (Fig. 5b) or 
5TGM1 (Fig. 5c) myeloma cells. Further, the inhibitory effect on myeloma cell viability 
induced by BTZ, DEX, or GSIXX remained intact when combined with Scl-Ab. These 
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results demonstrate that Scl-Ab does not affect myeloma cell viability and does not interfere 
with the efficacy of anti-MM drugs to induce myeloma cell death in vitro.
Discussion
Recent advances in the treatment of MM have significantly increased patient survival; 
however, the skeletal sequelae persist even in patients with complete remission (2). 
Bisphosphonates, the mainstay of MMBD therapy, prevent bone loss but further decrease 
bone formation and adversely affect bone quality (28). Therefore, agents that build new bone 
and improve MMBD but do not increase MM growth are an unmet need. Here we show that 
in bone colonized by myeloma cells, osteocytes overproduce Scl, an antagonist of Wnt/β-
catenin signaling that potently inhibits bone formation (Fig. 6) (17). Genetic deletion of Sost 
in immune-deficient mice prevents MMBD in the early phase of MM, and pharmacological 
inhibition of Scl increases bone formation and decreases osteolysis in immune-competent 
mice with established active MM. Mechanistic studies demonstrated that Sost/Scl inhibition 
overcame MM-induced osteoblast suppression, stimulated new bone formation, and partially 
blocked the increase in osteoclasts. Further, inhibition of Sost/Scl did not alter tumor growth 
in vivo or the efficacy of anti-myeloma drugs in vitro. Taken together, these results highlight 
the importance of Scl production in the MM microenvironment and provide the rationale for 
combining anti-myeloma drugs with Scl-Ab to simultaneously prevent tumor progression 
and stimulate osteoblast function to improve MMBD.
Our findings support the notion that overproduction of Scl by osteocytes participates in the 
suppression of new bone formation in MM. Multiple causes contribute to osteoblast 
inhibition in MM, including several Wnt inhibitors, blockade of Runx2, and secreted factors 
(29, 30). Activation of Wnt signaling induces osteogenesis by directly stimulating Runx2 in 
osteoblasts and enhances osteoblast/osteocyte survival (31, 32). Thus, it is likely that Scl-Ab 
overcomes MM-induced Runx2 blockade as well as prevents osteoblast/osteocyte apoptosis. 
Moreover, Scl-Ab therapy also increases bone formation on quiescent surfaces via 
modeling-based bone formation that does not require previous osteoclast activity (18, 33, 
34). Therefore, it is possible that the effects observed with Scl-Ab therapy in our model of 
MM are due to recruitment of unaffected osteoblasts or activation of bone lining cells 
covering quiescent bone surfaces to become bone forming cells (35). In addition, we 
recently demonstrated that activation of β-catenin signaling in osteocytes is sufficient to 
stimulate osteoblast differentiation and matrix synthesis (11), suggesting that autocrine 
effects of Wnt signaling in osteocytes could also contribute. Further studies are warranted to 
identify the specific mechanisms by which Scl-Ab overcomes osteoblast suppression in 
MM. Moreover, whether the Scl-Ab prevented the development of new lesions or promoted 
the filling of eroded areas was not addressed in our study and warrants future investigation.
Consistent with the current study, an earlier report showed that Scl-Ab prevented the 
decrease in bone volume in a mouse model of early MM (21). However, the cellular 
mechanism(s) underlying this effect was not studied. Herein, we demonstrate that the 
increases in bone mass induced by Sost/Scl inhibition result mainly from increased 
osteoblasts and stimulation of their function, resulting in new bone formation even in areas 
colonized by myeloma cells. Indeed, the protective bone effects are independent of the 
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presence of MM cells, as mice with low and high tumor burden were equally protected 
(Suppl. Fig. 1).
Our results also suggest that the increased Scl levels in the MM microenvironment may have 
a direct role inhibiting osteoclast differentiation, thus potentially contributing to the 
improvement of MMBD. However, no changes in circulating levels of the bone resorption 
marker CTX were detected, likely due to restriction of the tumor cells to the marrow 
compartment of the injected tibia. Nevertheless, these results are consistent with previous 
findings from our laboratory showing that Sost−/−/Scid mice are protected from GC-induced 
bone resorption (36), and with clinical and animal data demonstrating that the bone gain 
achieved by Scl-Ab therapy, although primarily due to stimulation of osteoblast activity, is 
accompanied by inhibition of bone resorption (37, 38). Multiple mechanism(s) may account 
for the inhibitory effects of Scl-Ab on osteoclasts. Inhibition of Sost/Scl, with the 
consequent increased Wnt/β-catenin signaling, could modulate resorption by upregulating 
OPG (15, 39). Scl also upregulates the expression of receptor activator of nuclear factor 
kappa-B ligand (RANKL) and increases osteoclast formation in vitro and in vivo (11, 40). 
Thus, Scl-Ab may reduce RANKL expression and, through inhibition of Wnt/β-catenin 
signaling, also directly inhibit osteoclast precursor differentiation (41).
Studies by Yaccoby and co-workers suggested that myeloma cells suppress osteoblast 
differentiation thereby blocking the anti-myeloma effects of mature osteoblasts, and that 
bone anabolic therapies not only improve MMBD, but also simultaneously control MM 
progression (42). However, we found that increased osteoblast numbers and function did not 
change MM growth in vivo or MM cell viability in vitro. Thus, the effect of osteoblasts on 
MM progression remains as an open question. Our findings that the increased osteoblast 
number induced by Sost/Scl inhibition does not interfere with tumor engraftment/growth are 
consistent with a recent report showing no differences in myeloma burden in mice with early 
stage MM treated with Scl-Ab and the lack of additive effects on MM growth when Scl-Ab 
was combined with Bortezomib (21). Similarly, neutralization of Dickkopf-related protein 
(DKK-1) in a murine model of MM abolished the suppression of osteoblastogenesis by MM, 
but had variable effects on tumor burden (43, 44). The stimulatory effects of Bortezomib on 
bone cells may contribute to the anti-myeloma properties of this drug (45). Thus, it is 
possible that different mechanisms underlie the actions of distinct bone anabolic therapies, 
and therefore some of them could exhibit anti-myeloma effects. Because Scl-Ab decreased 
MM-induced bone resorption, we cannot exclude the possibility that prolonged therapy with 
Scl-Ab may have anti-myeloma effects by affecting osteoclast support of MM growth, or 
increase the susceptibility of myeloma cells to anti-myeloma therapy when combined with 
other anti-myeloma agents.
Our data showing that Scl-Ab does not interfere with drugs that induce MM cell apoptosis 
via diverse mechanisms suggest that therapies combining Scl-Ab with anti-myeloma drugs 
could result in both beneficial skeletal outcomes and inhibition of tumor progression. 
Additionally, Scl-Ab therapy may prevent some of the adverse skeletal effects of anti-
myeloma drugs, such as glucocorticoids (46–48), as genetic deletion of Sost protects from 
glucocorticoid-induced bone loss (36).
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In conclusion, our study demonstrates that Scl is a promising target for the treatment of 
MMBD. Scl-Ab therapy stimulates new bone formation in areas colonized by myeloma 
cells, thus providing potential new avenues to improve bone disease in patients with active 
MM. Whether patients in complete remission or patients with monoclonal gammopathy of 
undetermined significance could benefit from pharmacological inhibition of Scl remains to 
be determined. Further, the current results support the notion that osteocytes contribute to 
the generation of a microenvironment that is favorable to MM progression and bone 
destruction, and suggest that targeting osteocytes and their derived factors represents a new 
and promising approach for the treatment of MM.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Genetic deletion of Sost decreases osteolysis and prevents bone loss induced by MM 
tumors without affecting tumor growth
(a) Experimental design (IT-intratibial injection). (b) Bone mineral density (BMD); *p≤0.05 
vs wt/Scid mice. (c) Serum human Kappa light chain 4-wks after cell inoculation (n.d., not 
detected). (d) Tibia X-rays and number/area of osteolytic lesions (n.d., not detected) 
*p≤0.05 vs wt/Scid JJN3-injected mice. (e) MicroCT images and microarchitecture of 
proximal tibia cancellous bone; # p≤0.05 vs wt/Scid (saline); *p≤0.05 vs saline-injected 
mice. Saline/JJN3-injected: n=7/9 wt/Scid and n=6/10 Sost−/−/Scid mice. Box plots: middle 
line in box represents the median, whiskers the 95% confidence interval of the mean, and 
circles are outliers from the 95% confidence interval. (BV/TV) is bone volume over tissue 
volume; (Tb.N) is trabecular number; (Tb.Th) is trabecular thickness and (Tb.Sp) is 
trabecular separation.
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Figure 2. Genetic deletion of Sost prevents the decrease in bone formation induced by myeloma 
cells
(a) Region of interest analyzed: cancellous bone of the proximal tibia and dynamic 
histomorphometric indexes and representative images of labeled bone surfaces; saline/JJN3-
injected: n=4/4 wt/Scid and n=5/6 Sost−/−/Scid mice; # p≤0.05 vs wt/Scid (saline); *p≤0.05 
vs saline injected mice. Static hystomorphometric quantification of osteoblasts (b) and 
osteoclasts (c) on bone stained with von Kossa and TRAPase; saline/JJN3-injected: n=7/9 
wt/Scid and n=6/10 Sost−/−/Scid mice; *p≤0.05 vs saline-injected mice. In figure b, red 
dotted lines indicate bone surfaces and yellow arrows point at osteoblasts. In figure c, black 
dotted lines indicate bone surfaces and yellow arrows point at TRAP positive osteoclasts. 
Abbreviations are as follows: Mineralizing surface over bone surface (MS/BS); mineral 
apposition rate (MAR); bone formation rate over bone surface (BFR/BS); osteoblast surface 
over bone surface (Ob.S/BS); osteoblast number over bone surface (Ob.N/BS); osteoclast 
surface over bone surface (Oc.S/BS); osteoblast number over bone surface (Oc.N/BS).
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Figure 3. Treatment with Scl-Ab reduces the number of osteolytic lesions and increases 
cancellous bone mass in mice with established MM disease
(a) Experimental design. (b) Serum IgG2b at 8-wks; saline/5TGM1-injected: n=9/9 IgG and 
n=10/7 Scl-Ab; *p≤0.05 vs saline injected mice. (c) Hematoxylin/eosin staining of the tibia; 
asterisk indicates the MM tumors. (d) Images and quantification of Scl positive osteocytes 
(Scl +ve Ot) in cortical and cancellous bone; saline/5TGM1-injected: n=3/3 IgG and n=3/3 
Scl-Ab; *p≤0.05 vs saline injected mice; red dotted lines indicate bone surfaces, red arrows 
point to Scl+ve Ot, and black arrows point to Scl-ve Ot. (e) Tibia X-rays and number of 
osteolytic lesions at 8-wks (n.d., not detected); saline/5TGM1-injected: n=9/9 IgG and 
n=10/7 Scl-Ab; *p≤0.05 vs 5TGM1-injected mice receiving IgG. (f) MicroCT images and 
bone microarchitecture; saline/5TGM1-injected: n=9/9 IgG and n=10/7 Scl-Ab; # p≤0.05 vs 
IgG-treated (saline) mice; *p≤0.05 vs saline-injected mice.
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Figure 4. Scl-Ab treatment increases osteoblasts in mice with established MM disease
Static histomorphometry quantification of osteoblasts (a) and osteoclasts (b) in bone of mice 
treated with IgG or Scl-Ab; # p≤0.05 vs IgG-treated (saline) mice; *p≤0.05 vs saline-
injected mice. Serum levels of P1NP (a) and CTX (b); # p≤0.05 vs IgG-treated (saline) 
mice; *p≤0.05 vs saline-injected mice. Saline/5TGM1-injected: n=9/9 IgG and n=10/7 Scl-
Ab (c) Black dotted lines indicated bone surfaces, yellow arrows point at osteoblasts, and 
red arrows point at TRAP positive osteoclasts.
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Figure 5. Scl-Ab does not alter the activity of anti-MM drugs
(a) Viability of human JJN3 and murine 5TGM1 myeloma cells treated with Bortezomib 
(BTZ), Dexamethasone (DEX) or the Notch inhibitor GSIXX alone, or in combination with 
Scl-Ab (b and c) for 48h; (n=4); *p≤ 0.05 vs. vehicle-treated cells (a) or vs. IgG-treated cells 
(b and c); bars represent mean ± SD. Similar results were observed in a separate experiment.
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Figure 6. Model showing the effects of Scl and Scl-Ab therapy in bone colonized by myeloma 
cells
In healthy bone, Scl modulates bone mass by antagonizing Wnt signaling to inhibit bone 
formation and stimulate bone resorption (left panel). In MM-colonized bone overproduction 
of Scl contributes to bone loss and osteolysis by suppressing osteoblasts function and 
increasing osteoclast numbers (middle panel). Blockade of Scl using Scl-Ab increases 
osteoblast number and stimulates new bone formation, and results in modest decreases in 
bone resorption, thus improving MM-induced bone disease (right panel).
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